Hepatitis B virus (HBV) infection is a major public health problem worldwide. The study aimed to evaluate the efficacy of pegylated interferon (Peg-IFN) alfa-2a treatment for seroclearance of HBs antigen (HBsAg) in HBe antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. This retrospective study investigated 16 HBeAg-negative CHB patients who received Peg-IFN alfa-2a weekly for 48 weeks. Thereafter, the patients were followed-up for 48 weeks after the end of therapy. The following criteria were also used for inclusion: HBV-DNA < 5.0 log copies/mL and without nucleot(s)ide analogs. Four HBsAg-positive cases became HBsAg negative. The HBsAg levels of the 4 patients who achieved HBsAg seroclearance were lower significantly than that of the non-seroclearance group (p = 0.007). The mean HBsAg levels in these 4 cases were 68 IU/mL, while the mean HBsAg levels in the non-seroclearance group were 2,114 IU/mL. The mean HBV-DNA levels in the 4 HBsAg seroclearance cases were 2.8 log copies/mL as compared to 3.6 log copies/mL in HBsAg-non-seroclearance cases (p = 0.01). Cases that are HBeAg negative, with HBV-DNA levels < 5 log copies/mL, and HBsAg titers < 120 IU/mL cases may achieve HBsAg clearance with Peg-IFN therapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Trépo C, Chan HLY, Lok A (2014) Hepatitis B virus infection. Lancet 384:2053–2063
Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97–107
Chen CJ, Yu MW, Liaw YF (1997) Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastoenterol Hepatol 12:294–298
Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73
Martinot-Peignoux M, Lapalus M, Laouénan C et al (2013) Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J ClinVirol 58:401–407
Qu LS, Liu JX, Zhang HF, Zhu J, Lu CH (2015) Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: a meta-analysis. Hepatol Res 45:1004–1013
Ono A, Suzuki F, Kawamura Y (2012) Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 57:508–514
Tseng TC, Liu CJ, Yang HC et al (2012) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142:1140–1149
Liu WR, Tian MX, Jin L et al (2015) High levels of hepatitis b surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads. Ann Surg Oncol 22:843–850
Hara T, Suzuki F, Kawamura Y et al (2014) Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients. J Viral Hepat 21:802–808
Brunetto MR, Moriconi F, Bonino F (2009) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49:1141–1150
Chen JD, Yang HI, Iloeje UH et al (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747–1754
Moucari R, Korevaar A, Lada O et al (2009) High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 50:1084–1092
Rijckborst V, Hansen B, Cakaloglu Y et al (2010) Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52:454–461
Tseng TC, Liu CJ, Yang HC et al (2013) Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 57:441–450
Tseng TC, Liu CJ, Chen CL et al (2013) Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 208:584–593
Sarin SK, Kumar M, Lau GK et al (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10:1–98
Kobayashi M, Hosaka T, Suzuki F, Akuta N et al (2014) Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol 49:538–546
Li MH, Zhang L, Qu XJ et al (2017) Kinetics of hepatitis B surface antigen level in chronic hepatitis B patients who achieved hepatitis B surface antigen loss during pegylated interferon alpha-2a treatment. Med J (Engl) 130:559–565
Moucari R, Mackiewicz V, Lada O et al (2009) Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151–1157
Wedemeyer H, Yurdaydin C, Dalekos GN et al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364:322–331
Marcellin P, Avila C, Wursthorn K et al (2015) Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 62:41–47
Boglione L, D’Avolio A, Cariti G et al (2013) Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 20:11–19
Jaroszewicz J, Ho H, Markova A et al (2011) B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 16:915–924
Kittner JM, Sprinzl MF, Grambihler A et al (2012) Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 54:93–95
We thank the technical assistants of the Department of Gastroenterology, Kagawa University.
This research was not directly funded.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval for this study was obtained from ethical committee of Kagawa University, Japan.
Human and animal rights statement
All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mimura, S., Fujita, K., Takuma, K. et al. Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg. Intern Emerg Med (2021). https://doi.org/10.1007/s11739-020-02622-7
- HBeAg negative
- Chronic hepatitis B